Ethos, an insurance technology startup, is exploring an initial public offering that could occur as soon as this year and has ...
The initial public offering (IPO) of National Stock Exchange (NSE) is perhaps one of most anticipated listings of the year.
Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of ...
Akebia Therapeutics shares were down 20% to $2.27 after the company priced its underwritten public offering of 25 million shares at $2 a share. All shares are being offered by Akebia. The proceeds to ...
Gross proceeds from the offering are expected to be approximately $4.5 million before deducting placement agent fees and estimated offering expenses. Castellum intends to use the net proceeds of the ...
The Company filed an amended and restated preliminary short form prospectus (the " A&R Prospectus ”) on March 20, 2025 with ...
Shares of Akebia Therapeutics fell after the company said it has commenced an underwritten public offering. The stock sank 21% to $2.24 in after-hours trading Wednesday. Shares ended the regular ...
The shares are being offered by Akebia pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (“SEC”) on September 3, 2024 and declared effective by the ...